Research theme for competitive and other funds (6)：
2025 - 2028 間歇型一酸化炭素中毒の病態解明および治療方法の究明
2020 - 2024 間歇型一酸化炭素中毒の病態解明及び治療の究明
2018 - 2020 ラットによる間歇型一酸化炭素中毒の病態解明及び治療の究明
2017 - 2019 The role of the ABCA7 gene in Alzheimer's disease
2016 - 2018 ラットによる間歇型一酸化炭素中毒の病態解明及び治療の究明
2013 - 2016 Association analyses between aminotransferase AGXT2 and mental disorders.
Show all
Papers (111)：
Naomi Hasegawa, Hiroyuki Muraoka, Yusuke Arai, Toru Horinouchi, Kazuhiro Yamamuro, Naoki Hashimoto, Shinichiro Ochi, Takashi Tsuboi, Yasushi Kawamata, Toshinori Nakamura, et al. Long-Term Impact of EGUIDE Training on Facility-Wide Guideline Adherence Rate in Schizophrenia and Major Depressive Disorder: A Multicenter Study. Neuropsychopharmacology reports. 2025. 45. 4. e70067
Shun Igarashi, Takashi Tsuboi, Naomi Hasegawa, Shinichiro Ochi, Kazutaka Ohi, Kentaro Fukumoto, Jun-Ichi Iga, Hiroyuki Muraoka, Hitoshi Iida, Fumitoshi Kodaka, et al. Maintenance pharmacotherapy after electroconvulsive therapy in inpatients with major depressive disorder: 198 prescriptions in a real-world clinical setting. BMC psychiatry. 2025. 25. 1. 957-957
Shinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, Takashi Tsuboi, Kazutaka Ohi, Shun Igarashi, Kentaro Fukumoto, Jun-Ichi Iga, Hiroyuki Muraoka, Hitoshi Iida, et al. Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study. The international journal of neuropsychopharmacology. 2025. 28. 4
Hiroaki Mori, Shinichiro Ochi, Hidetoshi Hashida, Jun-ichi Iga, Shu-ichi Ueno. Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review. Clinical Psychopharmacology and Neuroscience. 2025. 23. 3. 520-525
The biomarker for major depressive disorder: Telomere. 2025. 292. 13. 1120-1124
*Shinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, Jun-Ichi Iga, Hiroko Kashiwagi, Hiroshi Komatsu, Hiromi Tagata, Takashi Tsuboi, Shusuke Numata, Hitoshi Iida, et al. ASSOCIATIONS OF CLOZAPINE AVAILABLE INSTITUTION AND THE DIAGNOSIS OF SUBGROUPS ABOUT TREATMENT-RESISTANT SCHIZOPHRENIA OR NOT WITH A HIGHER RATE OF ANTIPSYCHOTIC MONOTHERAPY AND LOWER OTHER CONCOMITANT PSYCHOTROPICS IN OVERALL SCHIZOPHRENIA TREATMENT: A REAL-WORLD NATIONWIDE STUDY. International Journal of Neuropsychopharmacology. 2025. 28. Supplement_1. i163-i164
越智紳一郎, 小高文聰, 長谷川尚美, 伊賀淳一, 柏木宏子, 小松浩, 田形弘実, 坪井貴嗣, 沼田周助, 飯田仁志, et al. Associations of clozapine available institution and the diagnosis of subgroups about treatment resistant schizophrenia with higher rate of antipsychotic monotherapy in overall schizophrenia treatment. 統合失調症研究(CD-ROM). 2024. 13. 1
Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study.
(The 35th CINP World Congress of Neuropsychopharmacology 2024)
Microglial changes of the delayed carbon monoxide encephalopathy rat model
(Neuroscience 2023 2023)
Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study.
(33rd CINP World Congress of Neuropharmacology 2022)
5-HT1A partial agonist tandospirone for behavioral and psychological symptoms in oldest-old patients with dementia in a specialized elderly nursing home
(6th Congress of Asian College of Neuropsychopharmacology 2019)
Decreased neural precursor cells and glial cells in the hippocampus with delayed carbon monoxide encephalopathy
(Neuroscience 2019 2019)
2024/05 - JSNP Excellent Presentation Award for CINP 2024 Associations of clozapine available institution and the diagnosis of subgroups about treatment resistant schizophrenia or not with higher rate of antipsychotic monotherapy and lower other concomitant psychotropics in overall schizophrenia treatment: A real-world nationwide study.
2022 - The Japanese Society of Neuropsychopharmacology Nabeshima Prize Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study.
2022 - The Japanese Society of Neuropsychopharmacology JSNP Excellent Presentation Award for CINP 2022 Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study.
2013/10 - 第23回日本臨床精神神経薬理学会・第43回日本神経精神薬理学会 合同年会 Meet the experts MIP賞
2006 - 第94回日本内科学会四国地方会 研修医奨励賞
Show all
Association Membership(s) (13)：
World Federation of Societies of Biological Psychiatry
, 日本認知療法・認知行動療法学会
, 日本認知症学会
, 日本認知・行動療法学会
, Society for Neuroscience
, The International College of Neuropsychopharmacology
, 日本神経精神薬理学会
, 日本神経化学会
, 日本生物学的精神医学会
, 日本スポーツ精神医学会
, 日本老年精神医学会
, 日本臨床精神神経薬理学会
, 日本精神神経学会
